Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Diluted Average) (2018 - 2026)

United Therapeutics' Shares Outstanding (Diluted Average) history spans 11 years, with the latest figure at $47.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 1.24% to $47.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.9 million, a 1.24% decrease, with the full-year FY2025 number at $47.9 million, down 1.24% from a year prior.
  • Shares Outstanding (Diluted Average) hit $47.9 million in Q4 2025 for United Therapeutics, roughly flat from $48.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for UTHR hit a ceiling of $49.7 million in Q4 2023 and a floor of $46.4 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $48.4 million across 5 years, with a median of $48.5 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 6.77% in 2021 and later decreased 2.41% in 2024.
  • Tracing UTHR's Shares Outstanding (Diluted Average) over 5 years: stood at $47.3 million in 2021, then increased by 2.54% to $48.5 million in 2022, then grew by 2.47% to $49.7 million in 2023, then dropped by 2.41% to $48.5 million in 2024, then dropped by 1.24% to $47.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for UTHR at $47.9 million in Q4 2025, $48.1 million in Q3 2025, and $48.5 million in Q2 2025.